<DOC>
	<DOCNO>NCT01019655</DOCNO>
	<brief_summary>The purpose study investigate whether heparin effective treatment pregnant woman risk thrombosis pregnancy-associated complication .</brief_summary>
	<brief_title>Heparin Pregnant Women With Thrombophilia</brief_title>
	<detailed_description>Women thrombophilia , i.e . carriage factor V leiden mutation , factor II prothrombin G20210A mutation reduce amount antithrombin III , protein C protein S , elevate risk thrombosis relate sequela . Specifically , pregnant woman thrombophilia risk pregnancy-associated thrombosis , pregnancy-associated thromboembolism well early miscarriage ( 20 week gestation ) late miscarriage ( 20 week gestation ) , preeclampsia , intrauterine growth retardation &lt; 10th percentile . Uncontrolled retrospective prospective study indicate therapy unfractionated heparin low molecular weight heparin pregnancy significantly reduce pregnancy complication improve maternal fetal outcome . The use low molecular weight heparin pregnancy safe complication rate 1 % 3 % , mainly thrombocytopenia bleed complication . Randomized trial adequately assess safety efficacy heparin pregnant woman thrombophilia available date . Thus , intend randomize pregnant woman thrombophilia week gestation 11 14 therapy nadroparin calcium ( fraxiparinÂ® ) 0.3 mL daily pregnancy six week post partum usual care . The primary end point study composite endpoint pregnancy-associated thrombosis , pregnancy-associated thromboembolism , early miscarriage ( 20 week gestation ) late miscarriage ( 20 week gestation ) , preeclampsia , intrauterine growth retardation &lt; 10th percentile . We hypothesize prophylactic therapy nadroparin calcium significantly reduce pregnancy complication pregnant woman thrombophilia .</detailed_description>
	<mesh_term>Thrombophilia</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Nadroparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Pregnant woman singleton pregnancy Age &gt; 18 year Ability understand inform consent form Allergy/hypersensitivity nadroparin calcium Heparinassociated thrombocytopenia Organ lesion risk bleed acute stomach/bowel ulcer , cerebral hemorrhage , cerebral aneurysm uncontrolled hypertension Liver and/or renal dysfunction Known hematologic disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>thrombophilia</keyword>
	<keyword>pregnancy</keyword>
	<keyword>heparin</keyword>
</DOC>